Global scholars and internal research teams to participate, unveiling the latest research outcomes and commercialization roadmaps
Presenting development milestones, clinical plans, and global licensing/business strategies for peptide-based core pipelines
D&D Pharmatech (KOSDAQ: 347850) announced on the 14th that it will host ‘D&D Pharmatech R&D Day 2026’ on November 3. The event will reveal R&D achievements for its core peptide-based pipelines, future clinical plans, and global technology transfer and commercialization strategies.
The company, led by CEO Seulki Lee and specializing in GLP-1 class drug development, will hold the event at the Grand InterContinental Seoul Parnas in Samseong-dong. The session is scheduled to run from 10:30 AM to 3:10 PM for institutional investors, analysts, and the media.
The event consists of a morning academic session featuring global scholars associated with the company’s core pipelines, followed by an afternoon session where management will present R&D results and business strategies. After examining the latest research trends in basic science, the discussion will transition to the current development status of the company’s primary pipelines, future clinical plans, and global commercialization strategies.
In the morning, D&D Pharmatech co-founders and renowned scholars in the fields of neurodegenerative diseases and radiopharmaceuticals will introduce the latest research results and the potential for new drug development. The first speaker, Dr. Ted M. Dawson, Director of the Institute for Cell Engineering at Johns Hopkins University School of Medicine, will present on the theme of ‘Target and Biomarker Discovery for Neurodegenerative Diseases Based on Single-cell Genomics and AI.’
Following this, Professor Valina L. Dawson of Johns Hopkins University School of Medicine will deliver a lecture titled ‘Targeted Therapy for Neuroinflammation in Parkinson's Disease: From Mechanism Elucidation to NLY01 and Beyond.’ She is expected to explain the mechanism of action and clinical significance of D&D Pharmatech’s major neurodegenerative disease pipelines.
The final presentation of the morning session will be led by Dr. Martin G. Pomper, Chair of the Department of Radiology at UT Southwestern Medical Center. As a co-founder of Z-Alpha, D&D Pharmatech’s radiopharmaceutical affiliate, Professor Pomper will speak on ‘Radiopharmaceuticals in Drug Development: Case Studies in Cancer and CNS,’ introducing the potential applications and latest clinical R&D trends of radiopharmaceuticals in oncology and central nervous system disorders.
In the afternoon, D&D Pharmatech’s executive team will present development milestones and future business strategies for its major pipelines. Senior Vice President Eun-ji Park, Head of Research and Development, will provide an ‘R&D Update’ detailing the latest research achievements and future clinical plans for the company’s peptide-based core pipelines and other major drug candidates.
Subsequently, Jeong-heon Kwak, Head of the Business Development Team, will share updates on ‘D&D Pharmatech Business Development,’ including the status of global technology transfers and joint development initiatives. He will also outline strategies for commercializing major pipelines and directions for expanding global partnerships.
Finally, CEO Seulki Lee will announce mid-to-long-term growth strategies aimed at elevating the company into a global biotech leader. He plans to share strategies for building a sustainable growth foundation and enhancing corporate value based on the clinical progress of core pipelines and global business development achievements. Each presentation will be followed by a Q&A session to discuss R&D outcomes and the company’s future vision with attendees.
“This R&D Day event is a significant occasion to highlight new scientific possibilities in drug development that form the foundation of our company alongside global scholars, while sharing the specific achievements of D&D Pharmatech’s accumulated peptide drug development capabilities and core pipelines,” said CEO Seulki Lee. “Based on the R&D milestones we have built, we will accelerate the clinical development of our major pipelines and continue to expand our global partnerships.”
He added, “We will continue to enhance the value of our pipelines through differentiated technology and systematic development strategies, growing into an innovative drug development company with global competitiveness.”
